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Plasma mevalonate concentrations in uremic patients
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Plasma mevalonate concentrations in uremic patients. Mevalonic acid
(mevalonate or MVA), is an obligate precursor in the biosynthetic
pathway of cholesterol. It is partially metabolized by the kidneys and its
plasma concentrations are an index of endogenous cholesterol synthesis.
The aim of the present study was to evaluate plasma MVA concentrations
in uremic patients with different degrees of chronic renal failure (CRF;
group A), and the effects of a single hemodialysis treatment on plasma
MVA in a group of patients with end-stage renal disease (ESRD; group
B). CRF patients exhibited a higher mean basal mevalonate concentration
(13.3 6.5 ng/ml) than control subjects (4.68 1.32 nglml; P < 0.001). A
statistically significant direct correlation was evident in CRF patients
between mevalonate and creatinine plasma levels (r = 0.86; P < 0.001). A
single hemodialysis treatment was associated with a significant reduction
of plasma mevalonate concentrations four hours after the hemodialysis
session (—57%; P < 0.001) and an increase up to the basal values 24 hours
after the end of the treatment. In conclusion, our results demonstrated: (i)
higher plasma MVA concentrations in patients with decreased renal
function; (ii) a direct relationship between plasma MVA levels and the
degree of kidney failure as expressed by ereatinine plasma concentrations;
and (iii) a clear cut reduction of elevated plasma MVA levels after a single
hemodialysis treatment.
Cardiovascular diseases are the major causes of morbility and
mortality in patients with end-stage renal disease. Abnormalities
of lipid metabolism are involved in the atherogenic process in
these patients. Among the atherogenic risk factors, high serum
total cholesterol has been reported in 31% of patients with
chronic renal failure (CRF) on peritoneal dialysis and in 10% of
subjects on hemodialysis treatment [1]. The majority of studies
reported a normal or reduced total cholesterol levels in CRF
patients under different dialysis treatment schedules [2—41 often
associated with a low levels of high-density lipoprotein cholesterol
[5]. The mechanisms underlying cholesterol metabolism in CRF
patients are still a matter of discussion.
Mevalonic acid (MVA) is the direct product of the rate-limiting
step in cholesterol synthesis catalyzed by 3-hydroxy-3-methylglu-
taryl-coenzyme A (1-1MG CoA) reductase. The MVA pathway has
been suggested to play a role in progressive renal disease [6] in
diabetic ncphropathy [7], in essential hypertension [8, 91 and the
lipid abnormalities in nephrotic syndrome [10, ii]. Plasma and
urinary MVA concentrations in humans correlate with cholesterol
production rates in normal subjects as well as in patients with
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different lipid disorders [12—161. The plasma MVA concentrations
in humans are determined by the balance between MVA produc-
tion (intracellular synthesis in response to HMG CoA reductase
activity) and MVA metabolism [17—19]. The liver appears to be
the main source of MVA production, while the kidneys are the
major site for metabolism via both the sterol and the shunt
pathways [19—21]. A fivefold rise in plasma mevalonate levels has
been reported by Kopito et a! [22], following bilateral nephrec-
tomy in rats. In addition, mice with CRF exhibited a significant
increase in plasma mevalonate levels with a concomitant decrease
in the urinary excretion of mevalonate [23].
The aim of the present study was to evaluate: (a) the relation-
ship between plasma MVA concentrations and the degree of
chronic renal failure; and (b) the effects of a single hemodyalisis
treatment on plasma MVA concentrations in uremic patients with
end-stage renal disease.
Methods
Patients
Group A. Twenty-two patients from our outpatient population,
(16 males, 6 females), aged 62 14 years, body mass index (BMI)
24 1.9 kg/rn2, with different levels of CRF, plasma ereatinine
range from 1.41 to 8.57 mg/dl (mean SD = 4.8 2.4), and a
24-hour protein excretion less than 2.5 g/day, were admitted to the
study. Ten out of the 22 patients were hypercholesterolemic (total
cholesterol > 240 mg/dl). Clinical characteristics, plasma creati-
nine levels, 24-hour urinary protein excretion, lipid and lipopro-
tein levels are reported in Table 1.
Group B. Eleven male patients with end-stage renal disease
(ESRD), aged 62 10 years, with BMI 22 2.3 kg/rn2, on regular
hemodialysis treatment (since 55 34 months of dialysis) were
included. Clinical characteristics, plasma creatinine values,
plasma lipids and lipoproteins are reported in Table 2.
Group C. Ten healthy males, aged 59.9 8 years, with a BMI
of 23 1.2 kg/rn2, formed the conlrol group. Creatinine plasma
levels and lipid profiles are shown in Table 3.
Normal subjects, patients in group A having creatinine levels
less than 5 mg/dl and all patients in group B were maintained
under a diet of 35 Kcal/kg/body wt (55% carbohydrate, 25% fat,
total cholesterol < 400 mg/day and P/S < 1, 20% protein).
Patients in group A with creatinine levels higher than 5 mg/dl,
were maintained under a diet containing 68% carbohydrate, 25%
fat (total cholesterol < 400 mg/day and P/S < 1) and 7% protein.
Hepatic and thyroid tests were in the normal range in all
908
Scoppola et a!: MVA in uremia 909
Table 1. Clinical characteristics, plasma creatinine, lipid and lipoprotein levels and 24/h urinary protein excretion
in all patients with chronic renal failure (CRF):
Age Creatinine Tot. Chol. HDL-Chol. LDL-Chol. Tg. ApoA ApoB
Name (years) Sex Etiology of CRF (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl)
Albuminuria
(mgI24h)
T.L. 77 m nephrosclerosis 1.41 222 43 156 117 171 123 <30
CA. 70 m nephrosclerosis 1.5 220 38 160 112 120 144 70
B.M. 71 m nephrosclerosis 1.64 253 33 189 153 153 181 0
P.C. 68 f nephrosclerosis 2.13 225 41 128 281 105 142 90
M.A. 69 m nephrosclerosis 2.3 297 44 218 167 120 131 80
P.S. 88 m lithiasis 2.84 175 36 127 63 98 113 60
D.E. 55 m nephrosclerosis 2.85 220 48 116 280 121 135 60
B.G. 62 m APKD 3.1 224 41 151 152 130 142 300
A.E. 55 f lithiasis 3.16 242 36 158 238 146 137 200
CI. 77 f nephrosclerosis 4.38 331 46 329 269 211 166 500
C.E. 63 m nephrosclerosis 4.46 221 29 151 208 82 140 0
D.L. 61 m ncphrosclerosis 4.98 199 43 133 119 128 127 80
V.M. 64 f nephrosclerosis 5.41 280 30 214 183 147 169 50
S.M. 65 f nephrosclerosis 5.9 260 22 185 266 123 156 70
P.P. 80 m nephrosclerosis 6.33 194 29 146 94 168 143 300
GA. 30 m Chronic GN 6.38 104 32 57 79 133 64 900
F.C. 50 m membranous GN 6.85 269 44 201 119 156 174 1600
M.L. 66 f interstit. nephr. 7.46 345 70 240 174 247 203 700
CO. 60 m nephrosclerosis 7.67 172 50 83 195 281 94 500
D.M. 54 m membranous GN 7.96 249 38 185 141 178 155 700
M.B. 46 m APKD 8.21 284 56 200 139 203 164 150
S.M. 33 m APKD 8.57 160 58 651 100 84 0
mean 62 4.8 233 41 161 177 150 140
14 2.4 56 11 63 75 49 32
* The LDL-cholesterol value was not calculated because of high triglyceride levels
Table 2. Clinical characteristics, plasma creatinine values, plasma lipids and apolipoproteins in 11 normocholesterolemic
patients with end-stage renal disease (ESRD):
Age Months of Tot. Chol. HDL-Chol. LDL-Chol. ApoA ApoB
Name (years) Sex dialysis (mg/dl) (mg/dl) (mg/dl) (mgldl) (mg/dl)
A.G. 64 m 53 168 33 110 122 78
G.S. 64 m 20 194 27 109 107 104
B.A. 72 m 32 137 40 67 133 96
B.G. 56 m 96 153 38 87 156 100
C.M. 48 m 63 183 28 116 150 116
FR. 70 m 110 202 40 138 177 143
M.G. 74 m 25 115 37 60 152 65
P.C. 40 m 6 125 46 65 148 89
SE. 65 m 78 174 56 98 175 82
A.A. 71 m 86 201 40 124 156 127
P.E. 64 m 38 122 27 71 142 81
mean 62 55 161 37 95 147 98
10 34 32 9 26 20 23
participants. Fourteen patients (group A) received ACE inliihi-
tors for hypertension. None of the patients were given medica-
tions known to affect cholesterol metabolism. All of the subjects
had previously signed an informed consent for this investigation.
Experimental design
Basal samples for creatinine, lipids and mevalonate determina-
tions were withdrawn at 9 am. after a 12 hour fast. Blood samples
for the mevalonate assay were heparinized and the plasma was
separated by centrifugation and then stored at —70°C. In group B,
plasma mevalonate concentrations were measured before (T-0),
at the end of the session (T-4) and 24 hours after (T-24). The
hemodialysis treatment started at 9 a.m.
Hem odialysis sets
The hemodialysis patients were treated for four hours with
buffer bicarbonate in the dialyzate, with blood flow rate 300 25
mi/mm, UF/hr .1 0.8 0.2 liter/hr. with a cuprophane membrane
hemodialyzer. At the start the first heparine bolus (1500 500
UI) was followed during the dialysis session by continuous infu-
sion of 3500 500 UI. Before the hemodialysis session at 9:30
a.m. the patients received a low fat (< 5%) cholesterol-free meal.
Assays
Serum creatinine, cholesterol 1241 and triglycerides [25] were
determined in whole plasma by enzymatic colorimetric methods
**
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Table 3. Clinical Characteristics, plasma lipids and creatinine values in 10 control subjects
Name
Age
(years) Sex
Creatinine
(mgldl)
Tot. Chol.
(mgldl)
HDL-Chol.
(mgldl)
LDL-Chol.
(mgldl)
Tg
(mgldl)
Apo Al
(mg!dl)
Apo B100
(mgldl)
V.F. 59 m 0.97 210 48 135 1117 132 92
M.A. 62 m 1.02 209 52 130 136 109 75
F.A. 50 in 0.8 192 46 116 152 144 102
TI. 72 m 0.72 183 47 111 126 155 99
N.G. 49 m 0.92 187 44 124 108 147 84
D.G. 57 m 1.1 196 46 134 79 133 69
Q.I. 66 m 1.06 201 49 121 155 129 77
I.M. 68 m 0.88 191 53 114 119 178 81
U.G. 51 m 0.92 185 46 115 121 154 109
E.T. 65 m 1.03 205 42 137 132 98 125
mean 59.9 0.94 195 47 123 124 138 91
8 0.11 9 4 10 21 23 17
using commercially available kits (Boehringer-Mannheim, Mann-
heim, Germany). Plasma HDL cholesterol concentration was
determined after precipitation of Apo B containing lipoproteins
with sodium phosphotungstate/magnesium chloride, as described
previously [26]. LDL-cholesterol was determined by Friedewald's
formula. Apolipoproteins A-I and B-100 were determined by
immunoturbidimetric assays (Boehringer-Mannheim). The 24-
hour albumin excretion rate was determined by radioimmunoas-
say (Amersham, UK). The plasma MVA concentrations were
quantified using an extension of our previously described method
[271. Briefly, plasma was incubated with Dowex 50 (H) to
convert free MVA to its lactone. The nonpolar lipids were
extracted in hexane, after the mevalonlactone from the acqueous
solution was extrated into CH2CI2-PrOH (9:1 vol/vol) which was
loaded into a Lc-Si silica cartridge for the purification. The
lactone was finally reconverted to free mevalonic acid and then
converted to its 3,5-bis(trifluoromethyl)benzyl ester. The trimeth-
ylsilyl ether derivate was then prepared and reconstitued in
n-octane for gas chromatography-mass spectrometry (CG-MS).
The CG column was routed into the ion source of a VG
Biotech-Quattro mass spectrometer. The amount of the derived
MVA was measured by Cl/MS using CH4 as reactant gas,
operating the spectrometer in the single-ion mode to enhance the
sensitivity and the accurancy of the analysis. All MVA concentra-
tions were assayed in duplicate.
Statistics
One-way analysis of variance (ANOVA) and paired or un-
paired t-tests were applied to the results. The relationship be-
tween the MVA and creatinine plasma levels were explored by
univariate regression analysis. A P value of < 0.05 was considered
to he statistically significant. Data are presented as means SD.
Results
Group A
The mean plasma total cholesterol levels were 281 34 mg/dl
in the hypercholesterolemic, 194 36 mg/dl in normocholcstcr-
olemic CRF patients (P < 0.01) and 195 9 mg/dl in the control
subjects, (hypercholesterolemic CRF vs. control subjects, P <
0.01). The mean mevalonate plasma concentrations were 12.8
6.9 ng/ml in hypercholesterolemic and 14.5 5.9 nglml in
normocholesterolemic CRF patients, both significantly higher
than in control subjects (4.68 1.32 ng/ml, P < 0.001; Fig. 1). As
shown in Figure 2, a significant direct correlation was noted
between plasma MVA and serum creatinine in group A (r = 0.86;
P < 0.001).
Group B
In the group of uremic patients on intermittent hemodialysis
treatment, mean basal (T-0) plasma MVA concentration was
17,2 5.63 ng/ml, three- to fourfold increased than in control
subjects (P < 0.001). Plasma MVA concentrations decreased to
7.4 1.61 ng/ml after the dialysis session (T-4; T-0 vs. T-4, P <
0.001) and then increased up to 17.7 3.3 ng/ml 24 hours after
the end of the hemodialysis session (T-24; T-4 vs. T-24, P < 0.001;
T-24 vs. T-0, P = NS; Fig. 3).
Two out of the 11 patients (P.C.; M.G.) were anephric and their
MVA plasma values were similar to those of non-nephrectomized
patients.
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Fig. 1. Mean plasma mevalonate concentrations (MVA) at 9:00 am, in (U)
hypercholesterolemic and () normocholesterolemic CRF patients (group A),
and in (LI) control subjects (group C); * < 0.001 versus group C.
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Discussion
The kidneys are the major site for the metabolism of circulating
MVA via both the sterol and shunt pathways, and all mammals,
including humans, participate to the clearance of the compound,
with no significant differences between males and females [281.
Moreover, the MVA, which is the obligate precursor in the
biosynthetic pathway of cholesterol, is also a precursor of other
several substances (such as isoprenoids) and has been proposed to
play an important role in progressive renal disease and essential
hypertension [291. The recent introduction of a highly sensitive
CG[C1]MS assay for MVA determination has provided a
method to investigate MVA metabolism in patients with renal
disease [27].
In this study, MVA was found to be markedly affected by renal
disease. Patients with CRF exhibited significantly increased
plasma MVA levels that paralleled the degree of renal failure, as
reflected by serum creatinine values. These results are in keeping
with previous studies in experimental animals, demonstrating a
fivefold rise in plasma MVA levels following bilateral nephrec-
tomy in rats [22] and an increased plasma MVA with a decreased
urinary excretion in CRF mice [231.
The conversion of MVA to squalene and sterol in the kidney is
confined to the proximal and distal convoluted tubules in the
cortex [201. Little activity is present in the glomerulus. Besides,
circulating MVA metabolism is different among species. In the rat
85% of this metabolism occurs in the renal tissues [201, while in
the monkey renal metabolism represents 42% and in the human
39 to 46% [21]. Data in experimental animal models have
demonstrated that uremia induces alterations in the metabolism
of MVA that are characterized by a reduction in the shunt
pathway activity with an inverse relationship with either plasma
BUN or creatinine [30], and an enhancement of the sterol
pathway, even in the presence of intact renal mass. This in turn
produces a large increase in the hepatic cholesterol and non-
saponificable products synthesized from circulating MVA levels
[301. Finally, in the liver of the same animal models, this enhance-
ment of sterologenesis directly correlates with plasma BUN and
creatinine values [20, 21, 30]. The clear cut increase of MVA
concentrations in our CRF patients is likely to result from the
T-4
Time from die ysis session, hours
Fig. 3. Mean plasma mevalonate conc ntrations (MV4) in uremic patients
before (T-0), four hours after (T-4) an 24 hours after (T-24) the hemodi-
alysis treatment; *P < 0.00] versus T-C and T-24.
reduced renal function. Alternatively, one might hypothesise an
increased MVA synthesis or a reduced utilization of MVA along
the sterol and non-sterol pathways.
The importance of MVA pathway in renal diseases has been
indirectly demonstrated by the beneficial effects of HMG CoA
reductase inhibition in animal models of progressive glomerular
injury [6, 31, 321. These effects are probably due to a combination
of multiple factors as the reduction of circulating lipoproteins, a
decrease in glomerular lipoprotein deposition, an influence on the
synthesis of isoprenoids and on the mesangial cell proliferation
[33]. Farnesyl GTP-binding proteins may be critical for mitogenic
signalling stimulated by growth factors [17]. Dolichol esterified
with phosphates is essential for the synthesis of glycoproteins
including transporters such as the Na7H antiport [7]. The
activity of Na/H antiport can be reduced by the HMG CoA
reductase inhibitors in diabetic patients with nephropathy [7]. A
previous study demonstrated that lovastatin is able to reduce
glomerular injury in the Dahl S rat [31. In this animal, hyperlip-
idemia and progressive renal disease occur and may be responsi-
ble, at least in part, for the initiation of glomerular injury.
Interestingly, the lovastatin treatment markedly reduced albumin-
uria and the blood pressure [34]. On the other hand, a recent
human study in vitro [9] suggested that metabolites of the meva-
Innate pathway other than cholesterol could potentially control
vascular functions and cardiovascular hemodynamics. The in vitro
exposure of human conductance vessels to lovastatin increased
the response to vasoconstrictors and decreased endothelium-
dependent and independent relaxations, The authors suggested
that metabolic disorders of the mevalonatc pathway might con-
tribute to the pathogenesis of cardiovascular diseases, including
essential hypertension [8, 9]. Therefore, the possibility exists that
alterations of MVA concentrations in CRF patients may exert
some effects on hypertension associated to chronic renal failure.
Given the above considerations, we sought to determine the
effects of hemodialysis treatment on plasma MVA concentrations.
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Fig. 2. Relationship between plasma mevalonate (MVA) and serum creati-
nine in patients of group A. r = 0.86; P < 0.01.
Plasma creatiriine, mg/dl
T-0 T-24
912 Scoppola et al: MVA in uremia
A single treatment reduces plasma MVA levels by 57%. At the
end of the dialytic session, MVA concentrations are in the upper
normal range reaching a plateau 24-hours after with levels three-
to fourfold higher than normal. The reduction after hemodialysis
of plasma MVA is likely to be due to the clearance of hemodia-
lyzer, since MVA has a molecular weight of 148 and a serum
protein binding of approximately 30%. Accordingly, the MVA
concentrations measured in plasma and ultrafiltrate samples in a
single hemofiltration session show similar values (data not
shown).
In conclusion, the high basal plasma MVA concentrations
observed in CRF patients directly correlate with the degree of
kidney failure, as expressed by creatinine plasma concentrations.
In patients with end-stage renal disease, a single hemodialysis
treatment acutely reduces plasma MVA levels to near to normal
values. The possible consequences of the elevated MVA concen-
trations in the 24 hours preceding the hemodialysis session in
uremic patients needs to be further investigated.
Reprint requests to Dr. Alessandro Scoppola, Divisione Malattie Dismeta-
boliche, Complesso Integrato Columbus, Via della Pineta Sacchetti, 506,
00168 Rome, Italy.
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